BRPI0821461A8 - Uso de canabinóides em combinação com um medicamento antipsicótico - Google Patents

Uso de canabinóides em combinação com um medicamento antipsicótico

Info

Publication number
BRPI0821461A8
BRPI0821461A8 BRPI0821461A BRPI0821461A BRPI0821461A8 BR PI0821461 A8 BRPI0821461 A8 BR PI0821461A8 BR PI0821461 A BRPI0821461 A BR PI0821461A BR PI0821461 A BRPI0821461 A BR PI0821461A BR PI0821461 A8 BRPI0821461 A8 BR PI0821461A8
Authority
BR
Brazil
Prior art keywords
cannabinoids
combination
antipsychotic
acid
antipsychotic drug
Prior art date
Application number
BRPI0821461A
Other languages
English (en)
Inventor
Kikuchi Tetsuro
Maeda Kenji
Robson Philip
Stott Colin
Guy Geoffrey
Original Assignee
Otsuka Pharma Co Ltd
Gw Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39144704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0821461(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd, Gw Pharma Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BRPI0821461A2 publication Critical patent/BRPI0821461A2/pt
Publication of BRPI0821461A8 publication Critical patent/BRPI0821461A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

USO DE CANABINÓIDES EM COMBINAÇÃO COM UM MEDICAMENTO ANTIPSICÓTICO A presente invenção está relacionada ao uso de um ou mais canabinóides em combinação com um ou mais medicamentos antipsicóticos para uso na prevenção ou tratamento de psicose e distúrbios psicóticos. De preferência, os (um ou mais) canabinóides são escolhidos do grupo: canabidiol (CBD); ácido canabidiólico (CBDA); tetrahidrocanabivarin (THCV); ácido canabidiólico (CBDA); tetrahidrocanabivarin (THCVA); canabicromeno (CBC); ácido canabicromênico (CBCA); canabigerol (CBG) e ácido canabigerólico (CBGA). De preferência, a medicação antipsicótica é uma medicação antipsicótica atípica.
BRPI0821461A 2008-01-04 2008-12-17 Uso de canabinóides em combinação com um medicamento antipsicótico BRPI0821461A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0800390A GB2456183A (en) 2008-01-04 2008-01-04 Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
PCT/GB2008/004217 WO2009087351A1 (en) 2008-01-04 2008-12-17 Use of cannabinoids in combination with an anti-psychotic medicament

Publications (2)

Publication Number Publication Date
BRPI0821461A2 BRPI0821461A2 (pt) 2015-06-16
BRPI0821461A8 true BRPI0821461A8 (pt) 2018-04-03

Family

ID=39144704

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821461A BRPI0821461A8 (pt) 2008-01-04 2008-12-17 Uso de canabinóides em combinação com um medicamento antipsicótico

Country Status (25)

Country Link
US (1) US9017737B2 (pt)
EP (3) EP2609928B1 (pt)
JP (1) JP5409650B2 (pt)
KR (1) KR101631518B1 (pt)
CN (1) CN101939017B (pt)
AR (1) AR070063A1 (pt)
AU (1) AU2008346285B2 (pt)
BR (1) BRPI0821461A8 (pt)
CA (1) CA2708921C (pt)
CL (1) CL2008003902A1 (pt)
CO (1) CO6290695A2 (pt)
ES (3) ES2751117T3 (pt)
GB (3) GB2456183A (pt)
HU (2) HUE046780T2 (pt)
IL (1) IL206784A0 (pt)
MX (1) MX2010007073A (pt)
NZ (1) NZ586648A (pt)
PE (2) PE20141249A1 (pt)
PL (2) PL2609928T3 (pt)
PT (2) PT2609928T (pt)
RU (1) RU2503448C2 (pt)
TW (2) TWI519299B (pt)
UA (1) UA103472C2 (pt)
WO (1) WO2009087351A1 (pt)
ZA (1) ZA201005443B (pt)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
GB2377218A (en) * 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
KR20070089151A (ko) 2004-11-16 2007-08-30 지더블유 파마 리미티드 카나비노이드의 새로운 용도
GB2459637B (en) * 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
US8772349B2 (en) * 2010-03-26 2014-07-08 Vivacell Biotechnology Espana, S.L. Cannabinoid quinone derivatives
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
US8445034B1 (en) 2010-11-02 2013-05-21 Albert L Coles, Jr. Systems and methods for producing organic cannabis tincture
US9775379B2 (en) 2010-12-22 2017-10-03 Syqe Medical Ltd. Method and system for drug delivery
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
AU2014302410B2 (en) * 2013-06-26 2019-06-13 Amgen Inc. CB1 receptor antigen-binding proteins and uses thereof
CN105848646B (zh) 2013-10-29 2019-10-22 艾克制药有限公司 包含大麻二酚的压制片剂、其制造方法以及此类片剂在口服治疗精神病症或焦虑症中的用途
AU2014340710B2 (en) 2013-10-29 2019-08-22 Echo Pharmaceuticals B.V. Compressed tablet containing delta 9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
DK3160558T3 (da) 2014-06-30 2020-04-27 Syqe Medical Ltd Strømningsregulerende indåndingsanordning
WO2016001922A1 (en) 2014-06-30 2016-01-07 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
EP3160565B1 (en) 2014-06-30 2021-08-18 Syqe Medical Ltd. Devices and systems for pulmonary delivery of active agents
US10099020B2 (en) 2014-06-30 2018-10-16 Syqe Medical Ltd. Drug dose cartridge for an inhaler device
CN106573118B (zh) * 2014-06-30 2020-07-03 Syqe医药有限公司 用于活性剂的肺部递送的方法、装置及系统
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
EP3954417A1 (en) 2014-06-30 2022-02-16 Syqe Medical Ltd. Method and device for vaporization and inhalation of isolated substances
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
US9539295B2 (en) 2014-12-05 2017-01-10 Bradley Michael Bohus Cannabidiol (CBD) enriched alcohol
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2542155B (en) 2015-09-09 2018-08-01 Gw Pharma Ltd Use of cannabidiol in the treatment of mental disorders
KR20180095674A (ko) 2015-12-22 2018-08-27 조게닉스 인터내셔널 리미티드 대사 저항성 펜플루라민 유사체 및 그 사용 방법
CN113499330A (zh) 2015-12-22 2021-10-15 周格尼克斯国际有限公司 芬氟拉明组合物及其制备方法
AU2017204945B2 (en) 2016-01-06 2022-11-10 Syqe Medical Ltd. Low dose therapeutic treatment
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
EP3478307A4 (en) 2016-06-29 2020-02-26 Cannscience Innovations Inc. DECARBOXYLATED CANNABIS RESINS, USES AND METHODS OF MAKING
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US20210069170A1 (en) 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
US11701348B1 (en) 2016-07-23 2023-07-18 Turtle Bear Holdings, Llc Psilocybin compositions
AU2017315273B2 (en) 2016-08-24 2021-04-29 Zogenix International Limited Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
US10835501B2 (en) 2016-10-01 2020-11-17 Indication Bioscience Llc Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
CN108078984B (zh) * 2016-11-23 2020-11-20 汉义生物科技（北京）有限公司 5-羟色胺和去甲肾上腺素再摄取抑制剂与大麻二酚的组合物及其应用
CN108143726B (zh) * 2016-12-02 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与5-ht2a受体拮抗剂及5-ht再摄取抑制剂的药物组合物及其用途
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
AU2017384392B2 (en) 2016-12-20 2023-05-25 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
US20190142851A1 (en) * 2017-11-16 2019-05-16 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid
CA3052974A1 (en) 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
US20210346346A1 (en) 2017-02-09 2021-11-11 Caamtech, Inc. Compositions comprising a serotonergic tryptamine compound
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
CA3084953A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
MX2020005517A (es) 2017-12-05 2020-11-09 Sunovion Pharmaceuticals Inc Formas cristalinas y metodos de produccion de las mismas.
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
EP3755318B1 (en) * 2018-02-20 2022-08-24 MyMD Pharmaceuticals, Inc. Genetically modified cannabis sativa plants and modified cannabinoid compounds for treatment of substance addiction and other disorders
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
MX2020014286A (es) 2018-06-20 2021-03-25 Lts Lohmann Therapie Systeme Ag Sistema terapeutico transdermico que contiene asenapina.
WO2020188569A1 (en) * 2019-03-20 2020-09-24 Bol Pharma Ltd. Methods and compositions for preventing or treating weight gain caused by psychiatric drugs
SG11202113266YA (en) 2019-06-04 2021-12-30 Sunovion Pharmaceuticals Inc Modified release formulations and uses thereof
CA3158059A1 (en) 2019-11-19 2021-05-27 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
CA3187303A1 (en) 2020-07-28 2022-02-03 Impello Biosciences, Inc. Methods and compositions for altering secondary metabolites in plants
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
US11337934B1 (en) 2021-04-08 2022-05-24 Lanny Leo Johnson Compositions including a cannabinoid and protocatechuic acid
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
IL136839A (en) * 2000-06-16 2006-12-10 Yissum Res Dev Co Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same
US7053092B2 (en) * 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
DE60202270T2 (de) * 2001-03-22 2005-05-19 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazolderivate mit cb1-antagonistischer wirkung
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AU2003226149A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Substituted aryl amides
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
GB2392093B (en) * 2002-08-14 2006-03-08 Gw Pharma Ltd Pharmaceutical formulations
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
DK1575590T3 (da) 2002-12-27 2008-02-11 Otsuka Pharma Co Ltd Carbostyrilderivater og serotoningenoptagelsesinhibitorer til behandling af sindsstemningslidelser
CN102172402A (zh) * 2003-05-23 2011-09-07 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
WO2005000830A1 (en) * 2003-06-24 2005-01-06 Gw Pharma Limited Pharmaceutical compositions comprising cabbinochreme type compounds
CA2537535A1 (en) * 2003-09-02 2005-03-10 Solvay Pharmaceuticals Gmbh Novel medical use of selective cb1-receptor antagonists
AU2004273865A1 (en) * 2003-09-18 2005-03-31 Merck & Co., Inc. Substituted sulfonamides
CA2550435A1 (en) * 2003-12-19 2005-07-14 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
WO2006017892A1 (en) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
GB0425248D0 (en) * 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
KR20070089151A (ko) * 2004-11-16 2007-08-30 지더블유 파마 리미티드 카나비노이드의 새로운 용도
FR2882931B1 (fr) * 2005-03-14 2007-05-18 Sanofi Aventis Sa Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique
PE20071092A1 (es) * 2005-12-08 2007-12-10 Aventis Pharma Inc Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico
JP2009537523A (ja) * 2006-05-15 2009-10-29 メルク エンド カムパニー インコーポレーテッド 三級アルコールのプロドラッグ
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
EP1867308B1 (en) 2006-06-12 2010-10-20 Camp Scandinavia Ab Frame for a hyperextension brace
US8481085B2 (en) * 2006-06-15 2013-07-09 Gw Pharma Limited Pharmaceutical compositions comprising cannabigerol
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
WO2008133884A2 (en) 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
US8889076B2 (en) * 2008-12-29 2014-11-18 Uop Llc Fluid catalytic cracking system and process

Also Published As

Publication number Publication date
EP3095452A1 (en) 2016-11-23
CN101939017B (zh) 2016-08-17
TW201436791A (zh) 2014-10-01
TW200936127A (en) 2009-09-01
US20110038958A1 (en) 2011-02-17
KR20100113099A (ko) 2010-10-20
HUE046780T2 (hu) 2020-03-30
CO6290695A2 (es) 2011-06-20
CN101939017A (zh) 2011-01-05
CA2708921A1 (en) 2009-07-16
GB0800390D0 (en) 2008-02-20
GB2456183A (en) 2009-07-08
GB201012953D0 (en) 2010-09-15
EP2609928A2 (en) 2013-07-03
PE20141249A1 (es) 2014-10-03
RU2503448C2 (ru) 2014-01-10
AR070063A1 (es) 2010-03-10
EP2249848A1 (en) 2010-11-17
JP5409650B2 (ja) 2014-02-05
UA103472C2 (uk) 2013-10-25
US9017737B2 (en) 2015-04-28
CA2708921C (en) 2018-03-20
ES2750728T3 (es) 2020-03-26
BRPI0821461A2 (pt) 2015-06-16
GB2468828A (en) 2010-09-22
ZA201005443B (en) 2011-04-28
PL3095452T3 (pl) 2020-05-18
KR101631518B1 (ko) 2016-06-24
MX2010007073A (es) 2010-12-02
EP2609928A3 (en) 2013-12-18
AU2008346285B2 (en) 2015-04-02
CL2008003902A1 (es) 2009-07-24
PT2609928T (pt) 2019-10-29
JP2011508765A (ja) 2011-03-17
EP2249848B1 (en) 2016-05-18
PT3095452T (pt) 2019-10-30
IL206784A0 (en) 2010-12-30
NZ586648A (en) 2012-12-21
EP3095452B1 (en) 2019-07-17
GB201216932D0 (en) 2012-11-07
PE20091361A1 (es) 2009-09-23
GB2468828B (en) 2012-11-07
ES2574155T3 (es) 2016-06-15
AU2008346285A1 (en) 2009-07-16
PL2609928T3 (pl) 2020-06-01
RU2010132649A (ru) 2012-02-10
ES2751117T3 (es) 2020-03-30
TWI519299B (zh) 2016-02-01
HUE047214T2 (hu) 2020-04-28
WO2009087351A1 (en) 2009-07-16
EP2609928B1 (en) 2019-07-17

Similar Documents

Publication Publication Date Title
BRPI0821461A8 (pt) Uso de canabinóides em combinação com um medicamento antipsicótico
Russo Cannabidiol claims and misconceptions
BR112014007519A2 (pt) composição farmacêutica compreendendo os fitocanabinóides canabidivarina (cbdv) e o canabidiol (cbd)
Johnston Flavonoid nutraceuticals and ionotropic receptors for the inhibitory neurotransmitter GABA
BRPI0911384A8 (pt) Canabinóides em combinação com agentes quimioterápêuticos não canabinóides (por exemplo, agentes de alquilação ou serm)
GB201108506D0 (en) Cannabinoids for use in the treatment of neuropthic pain
EA201290975A8 (ru) Применение фитоканнабиноида каннабидиварина (cbdv) для лечения эпилепсии
BR112012025592A2 (pt) moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos
CO2020009747A2 (es) Métodos para purificar cannabinoides usando cromatografía líquido-líquido
BR112015014372A2 (pt) inibidores de autotaxina
IL291864A (en) Combinations of cannabinoids and acyl-ethanol-amines
Zenkov et al. Plant phenols and autophagy
US10596159B2 (en) Method and composition for treating cachexia and eating disorders
BR112017007774A2 (pt) Um ou uma combinação dos fitocanabinoides canabidiol (cbd); canabidivarina (cbdv); e tetra- hidrocanabivarina (thcv), combinação dos fitocanabinoides, formulação farmacêutica, e, método para tratamento de um indivíduo que sofre de distrofia muscular de duchenne (dmd).
BRPI0718176B8 (pt) formulação semissólida de liberação prolongada e controlada, processo para a preparação da composição farmacêutica semissólida
Bis-Humbert et al. Decreased sensitivity in adolescent versus adult rats to the antidepressant-like effects of cannabidiol
BR112013017750A2 (pt) nanocápsulas com envoltório polimérico
BR112015013096A8 (pt) conjunto de seringa e haste do êmbolo de seringa alongada
GB201120067D0 (en) Phytocannabinoids for use in the treatment of intestinal inflammatory diseases
GB2564459A8 (en) Use of cannabinoids in the treatment of a neurodegenerative disease or disorder
Zhou et al. Morusin inhibits the growth of human colorectal cancer HCT116‑derived sphere‑forming cells via the inactivation of Akt pathway
Di Majo et al. Flavonols and flavan-3-ols as modulators of xanthine oxidase and manganese superoxide dismutase activity
Yoshino et al. Oseltamivir (Tamiflu®) increases dopamine levels in the rat medial prefrontal cortex
BR112013002832A2 (pt) composição compreendendo retinol, um precursor ou um produto de reação do mesmo e um extrato vegetal de pelo menos uma planta de camomila para o tratamento de câncer
BR112014017656A2 (pt) composto, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: GW PHARMA LIMITED (GB) , OTSUKA PHARMACEUTICAL CO. LTD (JP)

Owner name: GW PHARMA LIMITED (GB) , OTSUKA PHARMACEUTICAL CO.

B25A Requested transfer of rights approved

Owner name: GW PHARMA LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: GW PHARMA LIMITED (GB)

B11R Patent application dismissed according to article 229 of the patent law [chapter 11.18 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2623 DE 13/04/2021.